Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Sells 1,535 Shares of Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Michael S. Brown sold 1,535 shares of the stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $1,040.00, for a total transaction of $1,596,400.00. Following the completion of the sale, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,437,280. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded up $7.10 during midday trading on Monday, hitting $1,043.62. 227,274 shares of the company’s stock were exchanged, compared to its average volume of 467,555. Regeneron Pharmaceuticals, Inc. has a 12-month low of $684.80 and a 12-month high of $1,049.50. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.51 and a current ratio of 5.27. The stock has a market cap of $115.00 billion, a price-to-earnings ratio of 30.86, a price-to-earnings-growth ratio of 2.14 and a beta of 0.13. The firm’s 50 day simple moving average is $956.29 and its 200 day simple moving average is $936.53.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.46 by ($0.49). Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. The business had revenue of $3.15 billion for the quarter, compared to analysts’ expectations of $3.19 billion. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.23 EPS for the current year.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of the business. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the 1st quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter worth $28,000. Fortitude Family Office LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $31,000. MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the 4th quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter worth $37,000. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

REGN has been the topic of several recent analyst reports. UBS Group upped their price objective on shares of Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a report on Wednesday, April 17th. JPMorgan Chase & Co. upped their price objective on shares of Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a report on Monday. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, April 30th. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. Finally, Sanford C. Bernstein started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, March 12th. They set an “outperform” rating and a $1,125.00 target price on the stock. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $998.09.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.